[Featured Stock] Amicogen Achieves 5x Productivity Technology in 89 Trillion Won Endolysin Market... $2,000 per Gram

[Asia Economy Reporter Hyungsoo Park] Amicogen is showing strong performance. The partnership with Lysando and the proven technology in the 89 trillion KRW-scale endolysin market appear to have influenced the stock price, according to securities firm analysis.

As of 9:51 AM on the 22nd, Amicogen is trading at 35,500 KRW, up 3.95% from the previous trading day.

Yang Hyungmo, a researcher at DS Investment & Securities, stated, "Amicogen has formed a strategic partnership with German Lysando, which possesses unique technology," adding, "The CEO of Lysando AG mentioned that thanks to Amicogen's technology, costs and time to market were reduced."

He continued, "By partnering with Amicogen, Lysando has gained access to the Asian market," and "They will quickly convert Lysando's research and development (R&D) achievements into market products."

Researcher Yang introduced, "Through this strategic partnership, Lysando is expected to provide the entire manufacturing process from the development of Artilysin to GMP," explaining, "Artilysin is used as an alternative to antibiotics against pathogenic bacteria, especially multi-drug resistant bacteria." He added, "It is used to restore the body's entire microbiome," and "The market size of endolysin researched by Lysando is 79 billion USD (89 trillion KRW)."

Furthermore, he said, "The reason Lysando needs Amicogen is due to the high cost," explaining, "The productivity of bacteriophage-related substances is very low, and endolysin suppliers can only produce 1 gram in a 1-liter tank." He emphasized, "Amicogen can produce 5 grams in a 1-liter tank," highlighting "five times the productivity compared to competitors."

Researcher Yang analyzed, "The trading price of endolysin is 3,000 to 5,000 USD per gram," and "Amicogen can supply Lysando at 1,000 to 2,000 USD based on its high productivity."

He forecasted, "This year, there are various potentials such as performance improvement of Amicogen China, collagen supply to Amorepacific, the start of the culture medium factory, and endolysin production issues," adding, "Although there are still uncertainties, if things go well, there is significant potential for stock price increase."